Kedrion Biopharma announced its support in the US of the Immune Deficiency Foundation (IDF) Research Grant Program for the second year in a row. Bio Products Laboratory (BPL) first provided the grant in 2022. In that same year, Kedrion joined forces with BPL forming the new Kedrion.
The IDF Research Grant Program is designed to encourage and support patient-oriented research on Primary Immunodeficiencies (PI), including well-defined research projects with a specified benefit for improving the treatment, health, management, or diagnosis of people with Primary Immunodeficiencies
“Once again, we’re excited to support IDF’s grant program,” said Eric Wolford, VP, Global Clinical Research and Operations for Kedrion. “Helping PI patients live healthier, happier lives is a goal we share with IDF, and we are pleased to reflect this ongoing commitment with another year of support for this research grant.”
According to Tracy Shaw, Chair of IDF’s Board of Trustees, “The continuation of this partnership represents our combined commitment to support studies that contribute to the body of medical knowledge in PI. The research funded through this program will advance IDF’s mission to improve the diagnosis, treatment, and quality of life of persons with primary immunodeficiencies.”
Primary Immunodeficiencies are a group of more than 450 rare, chronic disorders in which part of the body’s immune system is missing or functions improperly. Because one of the most critical functions of the normal immune system is to protect against infection, patients with PI commonly have an increased vulnerability to recurrent and sometimes severe and debilitating infections.
For more information about the IDF Research Grant Program, contact Christopher Scalchunes at [email protected].
